Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532.

Background The National Wilms Tumor Study (NWTS) approach to treating stage III favorable-histology Wilms tumor (FHWT) is Regimen DD4A (vincristine, dactinomycin, and doxorubicin) and radiation therapy. Further risk stratification is required to improve outcomes and reduce late effects. We evaluated clinical and biologic variables for patients with stage III FHWT without combined loss of heterozygosity (LOH) at chromosomes 1p and 16q treated in the Children's Oncology Group protocol AREN0532. Methods From October 2006 to August 2013, 588 prospectively treated, centrally reviewed patients with stage III FHWT were treated with Regimen DD4A and radiation therapy. Tumor LOH at 1p and 16q was determined by microsatellite analysis. Ineligible patients (n = 5) and those with combined LOH 1p/16q (n = 40) were excluded. Results A total of 535 patients with stage III disease were studied. Median follow-up was 5.2 years (range, 0.2 to 9.5). Four-year event-free survival (EFS) and overall survival estimates were 88% (95% CI, 85% to 91%) and 97% (95% CI, 95% to 99%), respectively. A total of 58 of 66 relapses occurred in the first 2 years, predominantly pulmonary (n = 36). Eighteen patients died, 14 secondary to disease. A better EFS was associated with negative lymph node status ( P < .01) and absence of LOH 1p or 16q ( P < .01), but not with gross residual disease or peritoneal implants. In contrast, the 4-year EFS was only 74% in patients with combined positive lymph node status and LOH 1p or 16q. A total of 123 patients (23%) had delayed nephrectomy. Submitted delayed nephrectomy histology showed anaplasia (n = 8; excluded from survival analysis); low risk/completely necrotic (n = 7; zero relapses), intermediate risk (n = 63; six relapses), and high-risk/blastemal type (n=7; five relapses). Conclusion Most patients with stage III FHWT had good EFS/overall survival with DD4A and radiation therapy. Combined lymph node and LOH status was highly predictive of EFS and should be considered as a potential prognostic marker for future trials.

[1]  James R. Anderson,et al.  Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532 , 2017, Annals of surgery.

[2]  James R. Anderson,et al.  Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. O'sullivan,et al.  Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Green,et al.  Considerations in the Diagnosis and Management of Pediatric Patients With Favorable Histology Wilms Tumor Who Present With Only Pulmonary Nodules , 2016, Pediatric blood & cancer.

[5]  K. Pritchard-Jones,et al.  Omission of doxorubicin from the treatment of stage II–III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial , 2015, The Lancet.

[6]  K. Pritchard-Jones,et al.  Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Pritchard-Jones,et al.  Biomarkers to detect Wilms tumors in pediatric patients: where are we now? , 2015, Future oncology.

[8]  R. Pieters,et al.  Response to the letter to the editor: 1q gain is a frequent finding in preoperatively treated Wilms tumors, but of limited prognostic value for risk satisfaction in the SIOP2009/Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) trial , 2015, Genes, chromosomes & cancer.

[9]  K. Pritchard-Jones,et al.  Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). , 2015, European journal of cancer.

[10]  R. Eils,et al.  Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. , 2015, Cancer cell.

[11]  Richard A. Moore,et al.  Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. , 2015, Cancer cell.

[12]  H. van Tinteren,et al.  Treatment of relapsed Wilms tumour (WT) patients: Experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG) , 2014, Pediatric blood & cancer.

[13]  N. Breslow,et al.  Breast cancer in female survivors of Wilms tumor: A report from the National Wilms Tumor late effects study , 2014, Cancer.

[14]  J. Dome,et al.  Risk stratification for wilms tumor: current approach and future directions. , 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[15]  N. Breslow,et al.  Outcome of patients with stage II/favorable histology wilms tumor with and without local tumor spill: A report from the National Wilms Tumor Study Group , 2014, Pediatric blood & cancer.

[16]  R. Pieters,et al.  Gain of 1q is a marker of poor prognosis in Wilms' tumors , 2013, Genes, chromosomes & cancer.

[17]  James R. Anderson,et al.  Gain of 1q is associated with inferior event‐free and overall survival in patients with favorable histology Wilms tumor: A report from the Children's Oncology Group , 2013, Cancer.

[18]  K. Pritchard-Jones,et al.  Surgical complications after immediate nephrectomy versus preoperative chemotherapy in non-metastatic Wilms' tumour: findings from the 1991-2001 United Kingdom Children's Cancer Study Group UKW3 Trial. , 2013, Journal of pediatric surgery.

[19]  Sebastiaan L. Knijnenburg,et al.  Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. , 2013, The Cochrane database of systematic reviews.

[20]  K. Pritchard-Jones,et al.  Incidence and outcomes of patients with late recurrence of Wilms' tumor , 2013, Pediatric blood & cancer.

[21]  N. Breslow,et al.  Clinicopathologic findings predictive of relapse in children with stage III favorable-histology Wilms tumor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Armstrong,et al.  Twenty‐five year follow‐up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study , 2011, Pediatric blood & cancer.

[23]  G. Sasso,et al.  Late Toxicity in Wilms Tumor Patients Treated With Radiotherapy at 15 Years of Median Follow-up , 2010, Journal of pediatric hematology/oncology.

[24]  Norman Breslow,et al.  Subsets of Very Low Risk Wilms Tumor Show Distinctive Gene Expression, Histologic, and Clinical Features , 2009, Clinical Cancer Research.

[25]  K. Pritchard-Jones,et al.  Value and difficulties of a common European strategy for recurrent Wilms’ tumor , 2009, Expert review of anticancer therapy.

[26]  N. Breslow,et al.  Early and late mortality after diagnosis of wilms tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N. Breslow,et al.  Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group , 2008, Pediatric blood & cancer.

[28]  D. Green,et al.  Controversies in the management of Wilms tumour - immediate nephrectomy or delayed nephrectomy? , 2007, European journal of cancer.

[29]  P. Sorensen,et al.  The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers , 2007, Nature Medicine.

[30]  N. Breslow,et al.  Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: A report from the National Wilms Tumor Study Group , 2007, Pediatric blood & cancer.

[31]  D. Machin,et al.  Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. , 2006, European journal of cancer.

[32]  N. Breslow,et al.  Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  N Graf,et al.  Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial , 2004, The Lancet.

[34]  P. Voûte,et al.  Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  M. Stöckle,et al.  Results of the SIOP 93-01/GPOH Trial and Study for the Treatment of Patients with Unilateral Nonmetastatic Wilms Tumor* , 2004, Klinische Padiatrie.

[36]  N. Breslow,et al.  Influence of radiation therapy delay on abdominal tumor recurrence in patients with favorable histology Wilms' tumor treated on NWTS-3 and NWTS-4: a report from the National Wilms' Tumor Study Group. , 2003, International journal of radiation oncology, biology, physics.

[37]  Dieter Harms,et al.  Revised International Society of Paediatric Oncology (SIOP) working classification of renal tumors of childhood. , 2002, Medical and pediatric oncology.

[38]  P. Voûte,et al.  Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  M. Gessler,et al.  Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors. , 2001, The American journal of pathology.

[40]  N. Breslow,et al.  Surgery-Related Factors and Local Recurrence of Wilms Tumor in National Wilms Tumor Study 4 , 1999 .

[41]  N. Breslow,et al.  Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Frappaz,et al.  High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: a French Society of Pediatric Oncology study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  C. Perez,et al.  Late effects of treatment for Wilms' tumor. , 1983, International journal of radiation oncology, biology, physics.

[44]  D. Machin,et al.  Risk factors for local recurrence in Wilms tumour and the potential influence of biopsy - the United Kingdom experience. , 2015, European journal of cancer.

[45]  D. Green,et al.  Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). , 2015, European journal of cancer.

[46]  D. Machin,et al.  An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour. , 2013, European journal of cancer.

[47]  P. Babyn,et al.  Wilms tumour: prognostic factors, staging, therapy and late effects , 2007, Pediatric Radiology.

[48]  M. Coppes,et al.  Management of Wilms' tumour: current practice and future goals. , 2004, The Lancet. Oncology.

[49]  A. Kelsey,et al.  Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group. , 2002, Medical and pediatric oncology.

[50]  N. Breslow,et al.  Surgical complications after primary nephrectomy for Wilms' tumor: report from the National Wilms' Tumor Study Group. , 2001, Journal of the American College of Surgeons.